31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Obesity and Area Deprivation Index, a measure of socioeconomic status, were significantly associated with elevated AD risk within the hypertensive cohort. 4 key findings →
Design: retrospective cohort Participants: 1,862 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The prevalence of hearing impairment and dementia increases with age but the nature of their association remains unclear. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
A+/High-EA individuals exhibited slower cognitive decline in global cognition and language domains than A+/Low-EA individuals. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
A total of 14 participants (2 in part A and 12 in parts B and C) completed at least 12 months of follow-up and were included in the analyses. 5 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. 4 key findings →
Participants: 215,970 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Age- and education-adjusted hazard ratios (HRs) for ADRD increased as neighborhood disadvantage increased, to 1.42 (95% confidence interval [CI] 1.06-1.91) in the most disadvantaged quintile compared to the least disadvantaged quintile, with a significant linear trend (p = 0.012). 5 key findings →
Design: longitudinal study Participants: 10,915 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
WMHs in the frontoparietal and anterior periventricular region were associated with blood pressure traits, WMH genetic risk score (GRS), baseline and decline in general cognitive performance, incident all-cause dementia, and ischemic stroke. 5 key findings →
Design: longitudinal study Participants: 2,878 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The mean age of participants was 77.1 years (SD = 7.6), and 2779 were women (weighted % = 56.7). 4 key findings →
Design: cohort study Participants: 1,238 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The sample included 740 donors (417 female [56.4%]; mean [SD] age at death, 81.5 [10.3] years; mean [SD] VBI score, 0.7 [1.0]; and median life course ADI, 7.08 [IQR, 4.33-9.83]), with residential years spanning 1905 to 2018. 5 key findings →
Design: cohort study Participants: 740 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Non-specific codes were most common. Alzheimer's and vascular dementia codes showed high regional variability. 5 key findings →
Design: cohort study Participants: 2,016 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We identified a total of 1,686,759 patients with incident dementia (mean (SD) age, 82.15 (6.90) years; 61.70% female) and 3,373,518 matched controls (mean (SD) age, 82.15 (6.90) years; 61.70% female). 5 key findings →
Design: cohort study Participants: 1,686,759 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The global rise in both metabolic syndrome (MetS) and neurodegenerative diseases (NDs), particularly dementia and Alzheimer's disease (AD) poses a growing health and socioeconomic burden. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
There were 13,145 individuals with risk factor data between 2015 and 2018 (51.1% aged 18-44, 31.0% aged 45-64, and 17.9% aged ≥65 years; 51.5% female after survey-weighting). 5 key findings →
Design: cross-sectional Participants: 13,145 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In a meta-analysis of 2 one-sample MR studies, the odds ratio (OR) for 1-SD higher BMI in predicting vascular-related dementia was 1.63 (95% CI, 1.13-2.35). 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 110 participants (mean [SD] age, 67.9 [4.6] years; 68 female [61.8%]) were randomized to the experimental group (n = 55) and the sham group (n = 55) and included in the intention-to-treat analysis. 5 key findings →
Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Green spaces generally showed an inverse association with EOD risk that was almost linear for AD and inverted U-shaped for non-AD. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Totally 7499 participants were included in the analysis, representing 40,728,543 community-living older Americans. 5 key findings →
Design: longitudinal study Participants: 7,499 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We found significant impacts of hypertension, diabetes and their comorbidity on cognitive impairment occurrence. 5 key findings →
Design: case-control study Participants: 40,103 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our analysis identified risk factors that contribute to sex differences in ADEN. 4 key findings →
Design: cohort study Participants: 128,769 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After adjusting for demographics, apolipoprotein E (APOE) ε4 status, cognition, and comorbidities, the highest tertile of REM latency was associated with higher Aβ burden (β = 0.08, 95% confidence interval [CI]: 0.03 to 0.13, p = 0.002), elevated p-tau181 (β = 0.19, 95% CI: 0.02 to 0.13, p = 0.002), and reduced BDNF levels (β = -0.47, 95% CI: -0.68 to -0.13, p = 0.013), compared to the lowest tertile. 5 key findings →
Participants: 128 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Between Sept 1, 2017, and Feb 28, 2019, 19 403 individuals were invited to participate and 9745 participants (1525 with dementia, 8220 without dementia) were included. 4445 (45·6%) of 9745 participants were male and 5300 (54·4%) were female. 5 key findings →
Design: cohort study Participants: 403 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 8994 and 14 720 participants were involved in the change-to-change analyses and change-to-dementia analyses, respectively. 5 key findings →
Design: longitudinal study Participants: 720 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
With aging, the hippocampal formation shows variable structural atrophy, which is associated with a decline in cognitive performance. 5 key findings →
Participants: 661 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Social isolation and loneliness were associated with a greater risk for incident dementia among T2DM individuals, with differential explanatory factors. 3 key findings →
Design: longitudinal study Participants: 24,986 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this cohort of 2022 insulin-treated older adults with diabetes and ADRD (1011 CGM users and 1011 SMBG users; mean [SD] age, 76.4 [6.7] years; 1133 female [56.0%]), CGM use was significantly associated with lower risk of all-cause hospitalization (hazard ratio [HR], 0.86; 95% CI, 0.76-0.96) and mortality (HR, 0.57; 95% CI, 0.48-0.67) compared with SMBG use. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events